Loading…
Based on limited metadata, the FDA issued a Warning Letter to Divyata, a drug manufacturer, on September 6, 2019. Without access to the full letter text or detailed subject information, the specific nature of the violations cannot be determined from the available metadata. The warning falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in the metadata provided. To understand the precise compliance issues cited, the complete Warning Letter would need to be reviewed.